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Human tick-borne diseases that are transmitted by Ixodes ricinus, such as Lyme borreliosis
and tick borne encephalitis, are on the rise in Europe. Diminishing I. ricinus populations in
nature can reduce tick exposure to humans, and one way to do so is by developing an anti-
vector vaccine against tick antigens. Currently, there is only one anti-vector vaccine avail-
able against ticks, which is a veterinary vaccine based on the tick antigen Bm86 in the gut of
Rhipicephalus microplus. Bm86 vaccine formulations cause a reduction in the number of
Rhipicephalus microplus ticks that successfully feed, i.e. lower engorgement weights and a
decrease in the number of oviposited eggs. Furthermore, Bm86 vaccines reduce transmis-
sion of bovine Babesia spp. Previously two conserved Bm86 homologues in I. ricinus ticks,
designated as Ir86-1 and Ir86-2, were described. Here we investigated the effect of a vac-
cine against recombinant Ir86-1, Ir86-2 or a combination of both on Ixodes ricinus feeding.
Recombinant Ixodes ricinus Bm86 homologues were expressed in a Drosophila expression
system and rabbits were immunized with rIr86-1, rIr86-2, a combination of both or ovalbu-
min as a control. Each animal was infested with 50 female adults and 50 male adults Ixodes
ricinus and tick mortality, engorgement weights and egg mass were analyzed. Although
serum IgG titers against rIr86 proteins were elicited, no effect was found on tick feeding be-
tween the rIr86 vaccinated animals and ovalbumin vaccinated animals. We conclude that
vaccination against Bm86 homologues in Ixodes ricinus is not an effective approach to con-
trol Ixodes ricinus populations, despite the clear effects of Bm86 vaccination against Rhipi-
cephalus microplus.
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Introduction
During a blood meal, Ixodes ricinus ticks can transmit several pathogens, including B. burgdor-
feri spp. and tick-borne encephalitis virus (TBEV), that cause Lyme borreliosis and tick-borne
encephalitis, respectively. Currently there is no vaccine available against Lyme borreliosis but
there are human vaccines available against TBEV. Other tick-borne pathogens, which are less
prevalent in humans, include Borrelia miyamotoi, Anaplasma phagocytophilum, Rickettsia spp.
and Babesia spp. The European Center for Disease Prevention and Control has predicted an in-
crease in the incidence of tick-borne diseases, caused by environmental, socio-economic and
demographic factors [1, 2]. In the Netherlands, with 17 million inhabitants, it is estimated that
there are more than one million tick bites each year [3].
To reduce the risk of human tick-borne diseases, preventive approaches to control tick den-
sities can be achieved by the use of acaricides [4]. However, resistance to acaricides in ticks can
occur, and acaricides are harmful for humans, animals and the environment. An alternative ap-
proach is an anti-tick vaccine which could lower tick densities as well as pathogen transmission
or acquisition [5]. The rationale for the development of a tick-antigen-based vaccine is based
on the observation that repeated exposure of certain animal species to tick bites results in the
inability of ticks to successfully take a blood meal on these animals, a phenomenon referred to
as tick immunity [6]. These animals develop hypersensitivity to ticks after repeated tick bites,
and are (partially) protected against tick-borne pathogens [7]. There are currently no vaccines
available against I. ricinus or other Ixodes tick species. So far, only one anti-tick vaccine has
proven successful in practice, namely a vaccine based on Bm86, which is a glycoprotein located
predominantly on the surface of tick midgut cells in Rhipicephalus microplus (formerly Boophi-
lus microplus) [8, 9]. Bm86 is a concealed antigen to which the host naturally does not develop
an immune response, since blood in the gut does not return to the host. A vaccine against
Bm86 is available as Gavac and used to be available as TickGARD Plus, but this has recently
been withdrawn from the market. Gavac is used in cattle in Latin America and is used to con-
trol tick populations by reducing the number of engorging R.microplus ticks, lowering en-
gorgement weights, and decreasing the number of oviposited eggs [10]. Bm86-based vaccines
also protect partially against infection of the parasite Babesia bovis. The function of Bm86 is
not fully understood, but the vaccine disrupts the tick gut during tick feeding [8]. Others have
shown the effect of Bm86-based vaccines on tick feeding in different tick species such as Rhice-
phalus annulatus, Rhipicephalus decoloratus,Hyalomma anatolicum and Hyalomma drome-
darii. In contrast, Bm86-based vaccines were not effective against Amblyomma cajennense,
Ambylomma variegatum and Rhipicephalus appendiculatus [11–14]. Several studies showed
that a vaccine based on Bm86 homologues, such as Haa86 from H. anatolicum and Hd86 from
Hyalomma scupense, resulted in lower numbers of engorging ticks after feeding on immunized
cattle [15, 16]. To the best of our knowledge, the efficacy of a Bm86-based vaccine against I.
ricinus has never been tested, although such a vaccine could theoretically impair I. ricinus feed-
ing and transmission of tick-borne pathogens relevant to the human situation, among which
B. burgdorferi. We have recently discovered two conserved Bm86 homologues in Ixodes ticks,
designated as Ir86-1 and Ir86-2. Quantitative RT-PCR confirmed transcription of both genes
specifically in the gut during adult I. ricinus feeding, suggesting that these proteins are—similar
to Bm86—concealed antigens [17]. Ir86-1 (Genbank: GU144602) consists of 619 amino acids,
with a predicted molecular weight of 68.0 kDa and is 30% identical and 49% similar to Bm86,
whereas Ir86-2 (Genbank: GU979808) consists of 610 amino acids with a predicted molecular
weight of 68.4 and is 28% identical and 45% similar to Bm86. Both Ir86-1 and Ir86-2 have a
GPI anchor, seven full EGF domains and one partial EGF domain [17]. In addition, a Bm86
homologue was also identified in Ixodes scapularis (Genbank: EEC05149), which is an
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important vector of tick-borne diseases in Northeastern parts of the United States of America
[18]. In this study we investigated whether immunizing against recombinant Ir86-1, Ir86-2 or
a combination of both in rabbits prevents successful feeding and reproduction of adult I. rici-
nus. These three vaccine strategies were tested in two subsequent experiments; in a pilot experi-
ment all three were tested in single rabbits followed by a second experiment in which the most
effective vaccine strategy was retested using three rabbits.
Material and Methods
Ethics statement
The Animal Care and Use Committee of the University of Amsterdam approved all animal ex-
periments (Permit number: DIX102900). Experiments have been conducted according to
national guidelines.
Animals and ticks
For the immunization six weeks old inbred New Zealand white rabbits (Charles River Labora-
tories) were used. I. ricinus adults (Singraven strain, the Netherlands) free from Borrelia spe-
cies, Anaplasma, Ehrlichia, Babesia and Theileria were purchased from the Utrecht Centre for
Tick-borne Diseases, Utrecht University, the Netherlands. Ticks were maintained at 23°C and
85% relative humidity under a 14 h light, 10 h dark photoperiod.
Purification of recombinant Ir86-1 and Ir86-2
Ir86-1 (Genbank GU144605.1) and Ir86-2 (GU979808.1) sequences were amplified from
I. ricinus cDNAs using primers Ir86_1_clone_FW CCATGGTCCCCTGTCCTTGGATTG,
Ir86_1_clone_RV 5’-CTCGAGCTTTTCCTCGCACAGGTTTC-3’ and 5’Ir86_2_clone_FW
CCATGGGTCATCGTCACGTGTTTG-3’ and Ir86_2_clone_RV CTCGAGTCTCTCACAACGT
TCTC excluding the signal peptide and GPI anchors regions in both proteins. PCR products
were ligated into the pGEM-T easy sequencing vector according to the manufacturer’s instruc-
tions (Promega, Madison, WI), transformed in DH5-alpha (Invitrogen, CA, USA) and plated
on LB-ampicillin plates. Single colonies were cultured into LB-ampicillin (50 μg/mL) and re-
combinant DNA was isolated using the Mini-prep KIT (Qiagen, Valencia, CA, USA). Inserts
were sequenced using Big Dye Terminator mix, M13 forward or reverse primers, and an auto-
mated sequencer (3730 DNA analyzer; all from AB Applied Biosystems, Foster City, CA).
From 20 clones, one clone for each protein was selected with the highest similarities to the pre-
vious identified sequences (100% for Ir86-1 and 98.8% for Ir86-2). Both sequences were cloned
in-frame into the pmt-bip-v5-his tag vector (Invitrogen, CA, USA). Stable transformants were
selected with blasticidin, expanded into a 1 L spinner flask and protein expression was induced
with copper sulfate and proteins were purified from the supernatant as described by the manu-
facturer (Invitrogen, CA, USA) using Ni-NTA chromatography cartridges (Qiagen, CA, USA)
[19]. The eluted fractions were desalted and concentrated in PBS with a 30 kDa cut-off spin
concentrator (Millipore, Billerica, MA). Protein purity was assessed by Coomassie blue on a
7.5% SDS-PAGE gel.
Detection of native Ir86-1 and Ir86-2 in I. ricinus gut lysate
Twenty I. ricinus female ticks were dissected to collect gut tissue and guts were homogenized in
200 uL PBS using a syringe. Tick gut lysate (5 μg) was separated by 10% SDS-PAGE and blotted
onto an PVDF-membrane. To detect the presence of native Ir86-1 or Ir86-2, we incubated the
PVDF-membrane with antiserum (1:200) from rabbits vaccinated against Ir86-1 or Ir86-2 (see
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below) and bound antibodies were detected using goat anti-rabbit IgG HRP (1:4000, Cell Sig-
naling, MA). As a control, antiserum from a rabbit vaccinated against ovalbumin was used.
Study design
Two experiments were performed in both of which four rabbits were immunized and infested
with I. ricinus adult ticks. In a pilot experiment (Experiment A) rabbits were vaccinated with ei-
ther rIr86-1, rIr86-2, a combination of rIr86-1 and rIr86-2 (from here on referred to as rIr86-
combination), or ovalbumin as a control. To validate the findings from experiment A, three an-
imals were vaccinated against rIr86-combination in a second experiment and one rabbit was
vaccinated against ovalbumin (Experiment B).
Vaccine formulations and rabbit immunization
Four different vaccines were used, namely rIr86-1 (100 μg rIr86-1 per immunization) rIr86-2,
(100 μg rIr86-2 per immunization) or rIr86-combination (50 μg rIr86-1 and 50 μg rIr86-2). As
a control we used ovalbumin (100 μg per immunization, Invitrogen, CA). Recombinant protein
in PBS solution was mixed 1:1 with complete Freund’s adjuvant at initial immunization and
with incomplete Freund’s adjuvant for boosters. All vaccines were injected subcutaneously, fol-
lowed by two boosts at 3 and 6 weeks and blood was collected via the ear vein before each vac-
cine was given. Two weeks after the last booster tick infestation was started (see below). Cut-off
for titer was calculated as OD pre-immune serum + 3 SD. Animals were monitored once a day
and had continuous access to food and water during the vaccination period. There was no indi-
cation for anesthesia or analgesia during the vaccination period.
ELISA assessment of antibodies in rabbit serum against rIr86-1 and
rIr86-2
V5-antibody (Invitrogen, CA, USA) was coated (1 μg/ml in PBS) on high binding microtiter
plates (Microlon, Greiner, Germany) overnight at RT. Wells were blocked with PBS/1% BSA at
RT for 1 h and incubated with rIr86-1 or rIr86-2 (1 μg/ml) diluted in PBS/ 0.05% Tween20/ 1%
BSA for 1 h. Wells were washed and incubated with diluted rabbit serum in PBS/1% BSA and
bound antibodies were detected using HRP-conjugated anti-rabbit IgG (Sigma, MO, USA) and
TMB as substrate (Sigma-Aldrich, MO, USA). Absorbance at 450 nm–650 nm was detected
using the iMark Microplate Reader (Biorad, CA, USA).
Tick infestation
Two weeks after the final boosters, 25 adult I. ricinus pairs were placed on each ear (50 I. ricinus
pairs in total per rabbit) in experiment A. To protect the ticks from manipulation by the rabbit,
ticks placed on the ears were protected by cotton socks taped to the ears and a neck collar (soft
eCollar, MDC exports, UK). In experiment B ticks were placed in an improved feeding cham-
ber, by placing them into a glued capsule on both shaved back flanks, protected by a collar and
a medical pet shirt (MPS, the Netherlands). Animals were monitored twice a day during the
tick infestation and had continuous access to food and water. There was no indication for anes-
thesia or analgesia during the tick infestation. After all ticks were collected from the rabbits,
serum was collected. Animals were anesthetized with Dexdomitor 0,25 mL / kg and Ketamine
(35 mg / kg) after which blood was collected from the cervical artery. After blood collection,
Euthasol (pentobarbital 100 mg / kg) injected via the ear vein was used to euthanize the rabbits.
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Tick collection and assessment of tick weight and egg mass
Fully engorged and detached female adult ticks were collected daily from the socks or feeding
chamber. Subsequently, ticks were weighted and stored individually in 2,0 mL Eppendorf
tubes, which were modified to allow air ventilation. Ticks were assessed for egg mass 6 weeks
post feeding.
Statistical analysis
The significance of the difference between the mean values of the groups was analyzed using
Prism 5.0 software (GraphPad Software, San Diego, CA). A one-way analysis of variance
(ANOVA) with the Tukey-Kramer multiple-comparison test for multi-group comparisons was
used, and p< 0.05 was considered significant.
Results
Expression of recombinant Ir86-1 and Ir86-2 and detection of native Ir86-
1 and Ir86-2 in I. ricinus gut lysate
The Ir86-1 and Ir86-2 coding sequences—without the GPI anchor and signal peptide—were
cloned and expressed in a Drosophila expression system (DES) using the pmt/bip/v5-his vector.
The rIr86-1 and rIr86-2 sequence were respectively 100% and 99% identical with the previously
identified sequences [17]. After purification, a Coomassie gel showed a molecular size of ap-
proximately 90–100 kDa for both proteins (Fig 1A). The presence of native Ir86-1 and Ir86-2
protein in the tick gut was confirmed by an immunoblot in which I. ricinus tick gut lysate was
probed with antiserum from rabbits immunized against rIr86-1 and rIr86-2 (Fig 1B).
Fig 1. Expression of recombinant Ir86-1 and Ir86-2 and detection of Ir86-1 and Ir86-2 in I. ricinus gut
lysate. A. Purified Drosophila-expressed recombinant Ir86-1 (Lane 1) and Ir86-2 (Lane 2) electrophoresed
on SDS 7.5% polyacrylamide gel and stained with Coomassie blue. B.Gut lysate from 20 adult female I.
ricinus tick guts electrophoresed on SDS 10% polyacrylamide gel stained with Coomassie blue (Lane 1) or
transferred to a PVDFmembrane which was probed with antiserum (1:200) from rabbits vaccinated against
rIr86-1 (Lane 2), rIr86-2 (Lane 3) or with antiserum from the control rabbit vaccinated against ovalbumin
(Lane 4).
doi:10.1371/journal.pone.0123495.g001
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IgG response against rIr86-1 and rIr86-2 in rabbits
Rabbits were vaccinated in two subsequent experiments, designated as Experiment A (pilot ex-
periment) and B (confirmatory experiment). A sandwich ELISA detecting antibodies against
rIr86-1 or rIr86-2 was performed to confirm serum reactivity against both proteins in rabbits.
In experiment A, in serum of the rabbit vaccinated against rIr86-1 we detected antibodies
against rIr86-1 and antibodies recognizing rIr86-2 were hardly present (Fig 2A and 2B). Simi-
larly, serum from the rIr86-2 vaccinated rabbit reacted with rIr86-2 and only to some extent
with rIr86-1 (Fig 2A and 2B). The serum from the rabbit vaccinated against rIr86-combination
responded similarly to rIr86-2, but lower to rIr86-1 compared to the single protein vaccinated
animals (Fig 2A and 2B). In experiment B, three rabbits were vaccinated against rIr86-
combination (Fig 2C). Using an ELISA with a rIr86-1 or rIr86-2 coating, we estimated that at
the start of tick feeding (t = 56) the IgG titer in the sera of these three rabbits against rIr86-1
and Ir86-2 was 1:105 and 1:106, respectively (Fig 2D).
Fig 2. Specificity and IgG response against rIr86-1 and rIr86-2 in experiment A (pilot experiment) and B (confirmatory experiment). IgG in serum
(1:10,000) was assessed with ELISA using 1 μg/mL of rIr86-1 and rIr86-2 on anti-V5 coated plates.A and B. IgG response in serum from animals in
experiment A vaccinated with rIr86-1 (circle), rIr86-2 (triangle), rIr86-combination (diamond) or ovalbumin (square) (n = 1 for each vaccine) reacting to rIr86-1
(A) or rIr86-2 (B). C.Mean IgG response in serum (1:10,000) from three animals vaccinated against rIr86-combination in experiment B measuring IgG
response to rIr86-1 (circle) or rIr86-2 (triangle).D.Mean IgG titer in serum from three animals vaccinated against rIr86-combination in experiment B, diluted
1:102 to 1:107 on ELISA coated with rIr86-1 (circle) or rIr86-2 (triangle). Error bars represent mean ± SEM.
doi:10.1371/journal.pone.0123495.g002
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Infestation of I. ricinus adults on rIr86-immunized or ovalbumin-
immunized rabbits
Two weeks after the second IFA boost (t = 56 days), the immunized rabbits were infested with
50 female I. ricinus adults and 50 male I. ricinus adults. In both experiments, tick repletion and
detaching took 7 to 9 days and no differences in numbers of engorged female ticks were seen
between the rIr86 vaccinated animals and control animals (ranging from 64–86%). In experi-
ment A, no differences were found between the animals that received rIr86-1 or rIr86-2 vacci-
nation compared to the ovalbumin vaccinated animal (Fig 3A and 3B). However, I. ricinus
Fig 3. I. ricinus infestations on rIr86-1, rIr86-2 or rIr86-combination vaccinated rabbits. Rabbits were infested with 50 I. ricinus adult females and 50 I.
ricinus adult males two weeks after the second boost (t = 56) in a pilot experiment (experiment A) and a confirmatory experiment (experiment B). Each
column on the x-axis represents one animal in experiment A (A and B) or experiment B (C and D).A. Post feeding female tick weight in experiment A, each
dot represents one tick. B. Egg mass from experiment A. Fed adult female ticks were stored individually. After 6 weeks, egg mass was weighted. Each dot
represent egg mass from one female tick. C. Post feeding female tick weight in experiment B. D. Egg mass from experiment B. Error bars represent
mean ± SEM. Mean values significantly different in a one-way analysis of variance (ANOVA) with the Tukey-Kramer multiple-comparison test for multi-group
comparisons are indicated by two asterisk (p < 0.01) or three asterisks (p < 0.001).
doi:10.1371/journal.pone.0123495.g003
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female engorgement weights were significantly lower in ticks that had fed on the rIr86 combi-
nation-vaccinated rabbit compared to ovalbumin (Fig 3A). No visual abnormalities (i.e. red-
ness in the body) were observed in ticks that had fed on the rIr86-combination rabbit. In line
with the reduced engorgement weights, egg weights were also significantly lower from ticks
that fed on the rIr86 combination-vaccinated rabbit compared to ovalbumin (Fig 3B). Howev-
er, these findings were not observed in experiment B, in which three rabbits were immunized
against the rIr86 combination and no differences in engorgement weights or egg mass were
found (Fig 3C and 3D). Together, the two experiments show that there were no significant ef-
fects on tick feeding with any of the three tested vaccines.
Discussion
Although a vaccine targeting Bm86 or its homologue in the tick gut has proven to be effective
against a number of tick species, our study shows that a vaccine based on the Bm86 homo-
logues in I. ricinus Ir86-1 and Ir86-2 does not prevent successful feeding of adult I. ricinus. We
were able to successfully immunize rabbits against rIr86-1 and rIr86-2 with low cross reactivity
of the antibodies and both proteins could be detected in the lysate of the guts from adult I. rici-
nus ticks. We chose CFA and IFA as vaccine adjuvants to ensure high IgG antibody develop-
ment. Using vaccines with both rIr86-1 and rIr86-2 resulted in a higher IgG response in serum
against rIr86-2 compared to rIr86-1, but the titer for both antigens was similar or even higher
compared to other vaccination studies [20, 21]. To study the effect of the vaccine on tick feed-
ing, our study was performed in a two-step approach. First, three different vaccine designs
were tested in a single rabbit after which the most effective vaccine was validated using three
rabbits to confirm our initial findings. Although vaccination with a combination of rIr86-1 and
rIr86-2 resulted in lower tick engorgement weights and egg mass in the pilot experiment, no
differences were found in the second confirmatory experiment. The initial findings in the pilot
experiment could be due to variance in animals or ticks. The same batch of purified recombi-
nant proteins and ticks from the same tick colony were used in both experiments. In addition,
the IgG levels in serum against rIr86-1 and rIr86-2 were similar in both experiments. We ob-
served a higher average tick weight in the second experiment compared to the first, e.g. 307 mg
(σ = 89.9) versus 227 mg (σ = 80.9) when comparing ticks that fed on the control vaccine rab-
bits. The only difference in experimental procedures between both experiments is that in ex-
periment A ticks were placed on the ears of the rabbits with a sock and collar as protection,
while in experiment B ticks were placed in plastic feeding chambers on the flanks to improve
protection from manipulation by the rabbits. In experiment A the rabbit receiving the rIr86-
combination might have experienced more severe itching at the tick bite site (the ear), and
more opportunity than the rabbits in experiment B to remove the ticks from the skin by itself.
Although this might have been a reason for the observed increased overall tick weights, it does
not explain the difference in phenotype between the two experiments.
We only studied the effect of this vaccine in rabbits and can therefore not predict whether
such a vaccine would be effective in other mammalian animal species. A possible explanation as
to why the rIr86 vaccine was not effective against I. ricinus in our model could be that the life-
cycle of I. ricinus is different from R.microplus. R.microplus is a one-host tick, which means
that ticks feed on one host during their life and ticks are exposed to serum antibodies from the
same individual at the larval, nymphal and adult life stage before laying eggs. I. ricinus is a three
host tick and in our study, ticks were only exposed to rIr86 antibodies at the adult feeding stage.
A repeated or prolonged exposure could be crucial for the efficacy of a vaccine against Bm86 or
Bm86-homologues. In addition, although CFA/IFA is a robust way of vaccinating and we did
observe high antibody titers, other vaccine formulations might also be worth investigating.
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Bm86 based vaccines are the only available commercial anti-tick vaccine and have showed
protection against several tick species. Although we did not see any effect, other studies have
reported other I. ricinus antigens as possible vaccine candidates to impact I. ricinus tick feeding
or pathogen transmission. Hajdusek et al. recently showed that the tick protein ferritin 2 in rab-
bit vaccination experiments lowered I. ricinus engorgements weights and reduced egg mass,
making it a potential candidate for an anti-I. ricinus vaccine [20]. Furthermore, a truncated
form of 64P has also been identified as a candidate for an anti-tick vaccine to prevent TBEV
transmission [21]. Finally, vaccination experiments in mice using I. scapularis salivary gland
proteins TSLPI, Salp15 and tHRF were effective in lowering B. burgdorferi transmission
[22–24]. However, none of the known candidates have made it to the market as an anti-tick
vaccine targeting Ixodes ticks. Future research should focus on the discovery of new vaccination
candidates, vaccine combinations and vaccination strategies against I. ricinus. Recently, a grant
was awarded to ANTIDotE, a consortium of seven European partners, which aims to deliver
vaccine candidates against I. ricinus and will explore how such vaccines could be implemented
in European health systems [2].
In conclusion, we successfully established antibody production against recombinant I. rici-
nus Bm86 homologues Ir86-1 and Ir86-2 in rabbits. However, using CFA and IFA, vaccinating
rabbits against rIr86-1, rIr86-2 or both did not interfere with adult tick feeding or egg
production.
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